港股医药板块集体走强，港股通创新药ETF易方达（159316）、港股通医药ETF易方达（513200）标的指数涨超2%

Core Viewpoint - The pharmaceutical industry is experiencing growth due to persistent human demand and unmet needs, alongside increased R&D investments by companies, marking the transition to an "innovation-driven" revenue era in China [1]. Group 1: Index Performance - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rose by 2.1% [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 2.0% [1]. - The CSI Biotechnology Theme Index saw a rise of 0.6% [1]. - The CSI Innovative Drug Industry Index grew by 0.4% [1]. - The CSI 300 Pharmaceutical and Health Index experienced a slight increase of 0.2% [1]. Group 2: Index Composition - The index focuses on leading innovative drug companies in A-shares, comprising no more than 50 stocks involved in innovative drug R&D [5]. - The index tracks leading biotechnology companies in A-shares, including no more than 50 stocks related to gene diagnostics, biopharmaceuticals, and other human biotechnology [7]. - The index covers leading companies in the pharmaceutical and health industry within the CSI 300, including segments like chemical pharmaceuticals, medical services, and medical devices [9]. Group 3: Valuation Metrics - The rolling P/E ratio for the innovative drug index is 50.4 times, with a valuation increase of 72.3% since its inception [6]. - The rolling P/E ratio for the biotechnology index is 53.2 times, with a valuation increase of 58.7% since its inception [8]. - The rolling P/E ratio for the CSI 300 Pharmaceutical and Health Index is 29.9 times, with a valuation increase of 39.2% since its inception [10].